The ‘PMR Research on Disease Mechanisms In Synovium’ (PROMIS) project is dedicated to unravelling the pathobiology of PMR. Ultrasound-guided synovial biopsies will be obtained from the subacromial-subdeltoid bursa of patients with PMR. A combination of immunohistochemistry and single-cell RNA sequencing will be applied to gain unprecedented insight into the synovial pathobiology of PMR.
The overarching aim of the PROMIS project is to identify synovial targets for treatment in PMR.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, Heeringa P, Brouwer E, Jiemy WF. Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Front Med (Lausanne). 2022 Jun 6;9:902155. doi: 10.3389/fmed.2022.902155. PMID: 35733858; PMCID: PMC9207253
Half of patients with PMR are currently ‘sentenced’ to prolonged use of glucocorticoids and frequently develop complications caused by this treatment. This project will accelerate the introduction of existing, targeted therapies (i.e. already used for other diseases) for patients with PMR by providing a clear rationale for such therapies. The ultimate goal of the study is to make long-term glucocorticoid therapy obsolete and to improve the patients’ well-being.